Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 0615-8625

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 0615-8625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Clopidogrel Tabs 8625 1)

Chemical structure of Clopidogrel bisulfate, showing the molecular arrangement with rings and functional groups including a thiophene ring, methyl ester, chlorine-substituted benzene ring, and associated bisulfate salt.*

FDA Label Image

Principal Display Panel (Clopidogrel Tabs 8625 10)

Clopidogrel bisulfate tablets, USP 75 mg, film-coated, in a quantity of 30 tablets. The label shows packaging and distribution information, including manufacturer ScieGen and labeler NCS HealthCare of KY, LLC dba Vangard Labs, Glasgow, KY. The label includes multiple barcodes and storage instructions at controlled room temperature.*

FDA Label Image

Principal Display Panel (Clopidogrel Tabs 8625 11)

Label sheet for Clopidogrel tablets USP 75 mg by NCS HealthCare of KY, LLC dba Vangard Labs. The sheet displays multiple repeat labels each stating "Clopidogrel Tablet, USP 75 mg" with lot number 8625 and barcode 5022812490. The bottom part of the sheet shows a detailed label including dosage strength, quantity of 30 tablets, storage instructions, manufacturer information by ScieGen, and barcodes.*

FDA Label Image

Figure1 (Clopidogrel Tabs 8625 2)

A horizontal dot plot showing the effect of various proton pump inhibitors (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) on clopidogrel active metabolite exposure (AUC). The x-axis represents the change relative to clopidogrel administered alone, ranging from 0.4 to 1.4. Mean values and 90% confidence intervals are displayed for each PPI's effect on the active metabolite AUC.*

FDA Label Image

Figure3 (Clopidogrel Tabs 8625 3)

A line graph titled 'Cardiovascular Death, Myocardial Infarction, Stroke' showing cumulative event rate (%) on the y-axis versus months of follow up (0 to 12) on the x-axis. Two lines represent event rates for patients receiving placebo (+ aspirin) and clopidogrel (+ aspirin), with the clopidogrel group showing a lower event rate over time. A p-value of 0.00009 is indicated, and a footnote states other standard therapies were used as appropriate.*

FDA Label Image

Figure3 (Clopidogrel Tabs 8625 4)

A set of forest plots comparing hazard ratios with 95% confidence intervals for Clopidogrel versus placebo across various patient subgroups. The plots include subgroups based on age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, heparin/LMWH use, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. Each subgroup's data shows number of patients, event counts with percentages, and visual hazard ratio markers indicating effects favoring Clopidogrel or placebo.*

FDA Label Image

Figure4 (Clopidogrel Tabs 8625 5)

A line graph titled 'Cumulative Event Rates for Death in the COMMIT Study,' showing the percentage of deaths before first discharge over 28 days since randomization. Two lines compare Placebo (8.1% deaths) and Clopidogrel (7.5% deaths), with a noted 7% proportional risk reduction (p=0.03). The graph includes a note that all treated patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Tabs 8625 6)

A Kaplan-Meier cumulative event curve comparing percentage of patients with death, re-infarction, or stroke before first discharge between Clopidogrel and placebo groups. The x-axis shows days since randomization (up to 28 days), and the y-axis shows percentage with events. Clopidogrel group shows a lower event rate compared to placebo, indicating a 9% proportional risk reduction.*

FDA Label Image

Figure6 (Clopidogrel Tabs 8625 7)

A forest plot chart showing the effects of adding clopidogrel to aspirin on primary endpoints across different patient subgroups in the COMMIT study. The chart compares odds ratios with confidence intervals between clopidogrel and placebo groups, segmented by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use.*

FDA Label Image

Figure7 (Clopidogrel Tabs 8625 8)

A cumulative event rate line graph comparing fatal or non-fatal vascular events over 36 months of follow-up between aspirin and clopidogrel. The y-axis shows cumulative event rate percentage, and clopidogrel line is consistently below aspirin, indicating lower event rates. A p-value of 0.045 is noted, indicating statistical comparison.*

FDA Label Image

Figure8 (Clopidogrel Tabs 8625 9)

A forest plot chart titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study' showing hazard ratios comparing Clopidogrel and Aspirin across different qualifying conditions: Stroke, MI, PAD, and Overall. The x-axis represents hazard ratio values from 0.6 to 1.3, indicating whether data favors Clopidogrel or Aspirin. Each subgroup's hazard ratio and confidence interval are plotted as diamonds along the axis, with corresponding patient counts and percentages listed for Clopidogrel and Aspirin groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.